Search results for "placebo-controlled"

showing 10 items of 93 documents

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia : results from a randomized, placebo-controlled …

2013

Purpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. Patients and Methods All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two hundred one patients were equally randomly assigned to receive either sorafenib or placebo between the chemotherapy cycles and subsequently for up to 1 year after the beginning of therapy. The primary ob…

MaleNiacinamideSorafenibOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPlacebo-controlled studyMedizinPlaceboDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProtein Kinase InhibitorsAgedAged 80 and overChemotherapybusiness.industryPhenylurea CompoundsConsolidation ChemotherapyMiddle AgedSorafenibSurgeryLeukemia Myeloid AcuteRegimenfms-Like Tyrosine Kinase 3OncologyTolerabilityMutationCytarabineFemalebusinessmedicine.drug
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Effect of nebulized beclomethasone on airway inflammation and clinical status of children with allergic asthma and rhinitis: a randomized, double-bli…

2012

We aimed to evaluate the therapeutic effect of nebulized beclomethasone dipropionate (nBDP) on both allergic asthma and rhinitis. In a randomized, double-blind, placebo-controlled study, 40 children (mean age 10.7 ± 2.1 years) with allergic asthma and rhinitis received either nBDP (daily dose of 800 µg, administered twice daily) or placebo for 4 weeks (with a face mask), after a 2-week run-in period of clinical assessment. Nasal and oral fractional exhaled nitric oxide (FeNO) measurements together with pulmonary function tests, nasal and oral exhaled breath condensate (EBC) collection for pH and interleukin-5 (IL-5) measurements as well as nasal and bronchial symptom scores were obtained at…

MaleVital capacityRhinitis Allergic PerennialAdolescentVisual analogue scaleImmunologyPlacebo-controlled studyPilot ProjectsPlaceboNitric OxidePulmonary function testingDouble-Blind MethodAdministration InhalationmedicineImmunology and AllergyHumansExhaled breath condensateAnti-Asthmatic AgentsChildAdrenergic beta-2 Receptor Agonistsrhinorrheabusiness.industryNebulizers and VaporizersBeclomethasoneGeneral MedicineImmunoglobulin EAsthmarespiratory tract diseasesRespiratory Function TestsBreath TestsAnesthesiaImmunologyExhaled nitric oxideFemalemedicine.symptomInterleukin-5businessbeclomethasone and asthma
researchProduct

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

2013

Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS). Definite/probable ALS patients, 40-70 years of age, duration 6-24 months, self-sufficient (i.e. able to swallow, cut food/handle utensils, and walk), and with forced vital capacity (FVC) > 80% entered a pilot double-blind, placebo-controlled, parallel group trial and were followed for 48 weeks. ALC or placebo 3 g/day was added to riluzole 100 mg/day. Primary endpoint: number of patients no longer self-sufficient. Secondary endpoints: changes in ALSFRS-R, MRC, FVC and McGill Quality of Life (QoL) scores. Analysis was made in the intention-to-tr…

Maleamyotrophic lateral sclerosisVital CapacityPlacebo-controlled studyPilot ProjectsGastroenterologylaw.inventionRandomized controlled triallawAcetyl-L-carnitineamyotrophic lateral sclerosis; motor neuron disease; randomized trial; acetyl-l-carnitinerandomized trialAmyotrophic lateral sclerosisAcetylcarnitineALS acetyl-L-carnitineNootropic AgentsRiluzoleMiddle AgedRiluzoleTreatment OutcomeNeurologyCombinationDisease Progressionmotor neuron diseaseDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAcetylcarnitinemedicine.drugAdultmedicine.medical_specialtyAcetyl-L-carnitine amyotrophic lateral sclerosis motor neuron disease randomized trialDouble blindDouble-Blind MethodDrug TherapyInternal medicinemedicineHumansAgedMED/26 - NEUROLOGIAbusiness.industryDisease progressionmedicine.diseaseAcetyl-L-carnitineSurgeryQuality of LifeAcetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nootropic Agents; Pilot Projects; Quality of Life; Riluzole; Treatment Outcome; Vital CapacityNeurology (clinical)businessExcitatory Amino Acid Antagonists
researchProduct

Do fatty acids help in overcoming reading difficulties? A double-blind, placebo-controlled study of the effects of eicosapentaenoic acid and carnosin…

2008

Background  There are claims that dietary supplementation of unsaturated fatty acids could help children with dyslexia to overcome their reading problems. However, these claims have not yet been empirically tested. Methods  This study was designed to test whether dietary supplementation was superior to placebo in treating reading, spelling or other reading-related skills of children with dyslexia. The experimental group (eicosapentaenoic acid, EPA, n = 30) ate dietary supplements and the control group (placebo, n = 31) placebos during the 90-day treatment period. The supplements contained omega-3 fatty acid (ethyl-EPA, 500 mg/day) and carnosine (400 mg/day). The groups were matched for read…

Malemedia_common.quotation_subjectPlacebo-controlled studyPlaceboDevelopmental psychologyDyslexiaDouble-Blind MethodReading (process)Developmental and Educational PsychologymedicineHumansChildFinlandmedia_commonchemistry.chemical_classificationCarnosinePublic Health Environmental and Occupational HealthDyslexiaFatty acidmedicine.diseaseEicosapentaenoic acidCombined Modality TherapySpellingTreatment OutcomechemistryEicosapentaenoic AcidCase-Control StudiesPediatrics Perinatology and Child HealthLearning disabilityDietary SupplementsFemalemedicine.symptomPsychologyClinical psychologyChild: care, health and development
researchProduct

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

2021

INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseli…

Malemedicine.medical_specialtyPROGNOSISChenodeoxycholic AcidPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineHumansBIOCHEMICAL RESPONSEAdverse effectCIRRHOSISRetrospective StudiesFenofibrateBezafibrateHepatologybusiness.industryLiver Cirrhosis BiliaryGastroenterologyObeticholic acidMiddle AgedBEZAFIBRATEUrsodeoxycholic acideye diseasesDiscontinuationURSODEOXYCHOLIC ACIDClinical trialTreatment Outcomechemistry030220 oncology & carcinogenesisAlkaline phosphatase030211 gastroenterology & hepatologyFemaleBezafibratebusinessmedicine.drug
researchProduct

Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal bac…

2013

Background The organic nitrate pentaerithrityl tetranitrate (PETN) has been shown to have ancillary properties that prevent the development of tolerance and endothelial dysfunction. This randomized, double-blind, placebo-controlled, multicentre study (‘CLEOPATRA’ study) was designed to investigate the anti-ischaemic efficacy of PETN 80 mg b.i.d. (morning and mid-day) over placebo in patients with chronic stable angina pectoris. Methods and results A total of 655 patients were evaluated in the intention-to-treat population, randomized to PETN (80 mg b.i.d., n = 328) or placebo ( n = 327) and completed the study. Patients underwent treadmill exercise tests at randomization, after 6 and 12 wee…

Malemedicine.medical_specialtyRandomizationmedicine.drug_classVasodilator AgentsPopulationAdrenergic beta-AntagonistsPlacebo-controlled studyPlaceboAdrenergic beta-AntagonistsMedication AdherenceDouble-Blind MethodmedicineClinical endpointHumansPentaerythritol TetranitrateAngina StableEndothelial dysfunctioneducationBeta blockereducation.field_of_studyExercise Tolerancebusiness.industryMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaDelayed-Action PreparationsChronic DiseaseExercise TestFemaleCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Epidural anesthesia: Simulated intravascular test dose with S(+) ketamine, lidocaine and adrenaline. A prospective, randomized, double blind and plac…

2015

Abstract Objective The use of a test dose in epidural anesthesia is a safety recommendation. However, specificity and sensitivity of the drugs used with this indication have not been conclusive. The main objective of this study was to compare the effectiveness and the adverse effects of a simulated intravascular test dose of adrenaline, lidocaine and S(+)-ketamine. Material and methods A prospective, randomized, double blinded, placebo controlled study was designed. ASA I patients scheduled for elective surgery were included. These were randomized to the following study groups: S(+)-ketamine 0.5 mg kg −1 (S+K group), 5% lidocaine 1.5 mg kg −1 (L5% group), adrenaline 15 μg (ADR group), and p…

Mean arterial pressureLidocainebusiness.industryPlacebo-controlled studyGeneral MedicineBlood pressureAnesthesiaHeart ratemedicineKetaminemedicine.symptombusinessAdverse effectTinnitusmedicine.drugRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Repercussions of intraalveolar placement of combination of 0.2% chlorhexidine & 10 Mg metronidazole gel on the occurrence of dry sockets- A randomize…

2017

BACKGROUND To evaluate the effects of intraalveolar placement of gel containing 0.2% chlorhexidine and 10gm of metronidazole on the incidence of alveolar osteitis. MATERIAL AND METHODS A total of 300 impacted third molars were extracted in 150 patients enrolled in this trial. In each subject a socket was randomly selected and packed to the crest of alveolar ridge with the gel. The contralateral socket was packed with placebo dressing. The occurrence of dry socket was assessed during 3rd and 5th postoperative days .The data was analysed using a meta analytical program. STUDY DESIGN Double blind, prospective, placebo controlled trial. RESULTS The combination of metronidazole + chlorhexidine g…

Molarmedicine.medical_specialtyPlacebo-controlled studyDentistryOdontologíaPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineAlveolar ridgeGeneral Dentistrybusiness.industryResearchChlorhexidine030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]equipment and suppliesCiencias de la saludSurgerybody regionsDry socketMetronidazole030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOral Surgerybusinessmedicine.drug
researchProduct